Clinical Management of Antiplatelet Drug Resistance in Patients With Drug Eluting Coronary Stents

Creighton University

Status and phase: Withdrawn; Phase 4

Conditions: Coronary Artery Disease

Treatments: Drug: Plavix (Clopidogrel)

Study type: Interventional

Funder types: Other

Identifiers

NCT00589862

07-14622

Details and patient eligibility

About

It is recommended that patients who have drug-eluting stents placed in their coronary arteries take aspirin and Plavix (Clopidogrel) for at least a year. Patients who stop taking these antiplatelet drugs or who have resistance to the antiplatelet effects of these drugs are at a higher risk of clots occurring inside the stents which may result in a heart attack. At the present time, it is unknown if increasing the doses of the antiplatelet agents is effective in overcoming this resistance. The purpose of this project is to identify patients with antiplatelet drug resistance and to test whether an increase in the Plavix (Clopidogrel) dose overcomes antiplatelet drug resistance.

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Required Coronary Artery Angioplasty with a drug-eluting stent deployment

Exclusion criteria

• The last drug-eluting stent placed greater than 2 weeks prior
• Aspirin or Plavix (Clopidogrel) allergy or contraindication

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

1

Experimental group

Treatment:

Drug: Plavix (Clopidogrel)